Background/Aims/Objectives: In patients elected to the first prostate biopsy set, the risk of prostate cancer (PCA) may be predicted by clinical factors. The aim of this study was to investigate on prostate volume index (PVI), defined as the ratio of volume of the transitional zone to the volume of the peripheral zone, and PCA risk. Methods: The study retrospectively evaluated 1,327 patients and included only the first biopsy set with 14 cores. PCA risk was assessed by using the multivariate logistic regression model. Results: The analysis evaluated 596 patients. The detection rate of PCA was 49%. Age, prostate specific antigen, PVI and digital rectal exam were independent factors of PCA risk, which was decreased by PVI (OR 0.224; 95% CI 0.157-0.380). The goodness of fit statistics assessed model efficacy. Conclusions: In a large cohort undergoing the first biopsy set, PVI associated with a decreased risk of PCA. Confirmatory studies are required.

Keywords:
Prostate volume index, Prostate cancer, Prostate biopsy, Prostate specific antigen , Prostate volume
1.
Selman SH: The McNeal prostate: a review. Urology 2011;78:1224-1228.
2.
De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, et al: The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011;60:106-117.
3.
Gandaglia G, Briganti A, Gontero P, Mondaini N, Novara G, Salonia A, et al: The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int 2013;112:432-441.
4.
Roobol MJ, Schröder FH, Hugosson J, Jones JS, Kattan MW, Klein EA, et al: Importance of prostate volume in the European randomised study of screening for prostate cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol 2012;30:149-155.
5.
Al-Azab R, Toi A, Lockwood G, Kulkarni GS, Fleshner N: Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology 2007;69:103-107.
6.
Ankerst DP, Till C, Boeck A, Goodman P, Tangen CM, Feng Z, Partin AW, Chan DW, Sokoll L, Kagan J, Wei JT, Thompson IM: The impact of prostate volume, number of biopsy cores and American urological association symptom score on the sensitivity of cancer detection using the prostate cancer prevention trial risk calculator. J Urol 2013;190:70-76.
7.
Tang P, Chen H, Uhlman M, Lin YR, Deng XR, Wang B, Yang WJ, Xie KJ: A nomogram based on age, prostate-specific antigen level, prostate volume and digital rectal examination for predicting risk of prostate cancer. Asian J Androl 2013;15:129-133.
8.
Djavan B, Zlotta AR, Remzi M, Ghawidel K, Bursa B, Hruby S, Wolfram R, Schulman CC, Marberger M: Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection? Urology 1999;54:846-852.
9.
Porcaro AB, Novella G, Molinari A, Terrin A, Minja A, De Marco V, Martignoni G, Brunelli M, Cerruto MA, Curti P, Cavalleri S, Artibani W: Prostate volume index and chronic inflammation of the prostate type IV with respect to the risk of prostate cancer. Urol Int 2015;94:270-285.
10.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
11.
Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, et al: Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst 2013;105:1050-1058.
12.
Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350:2239-2246.
13.
Augustin H, Mayerhofer K, Seles M, Pummer K: Is there a role for active surveillance in low-risk prostate cancer? Urol Int 2015;95:125-131.
14.
Romero-Otero J, García-Gómez B, Duarte-Ojeda JM, Rodríguez-Antolín A, Vilaseca A, Carlsson SV, Touijer KA: Active surveillance for prostate cancer. Int J Urol 2016;23:211-218.
15.
Schoots IG, Petrides N, Giganti F, Bokhorst LP, Rannikko A, Klotz L, et al: Magnetic resonance imaging in active surveillance of prostate cancer: a systematic review. Eur Urol 2015;67:627-636.
16.
Albertsen PC: Observational studies and the natural history of screen-detected prostate cancer. Curr Opin Urol 2015;25:232-237.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.